Aquestive therapeutics completes fda type a meeting on libervant

Warren, n.j., nov. 18, 2020 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today the completion of a type a meeting with the u.s. food and drug administration (fda) confirming a pathway for resubmission for approval of the company's drug candidate libervant™ (diazepam) buccal film for management of seizure clusters.
AQST Ratings Summary
AQST Quant Ranking